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Abstract
Introduction: Celecoxib, a highly specific cyclooxygenase-2 (COX-2) inhibitor has been reported to have COX-2-
independent immunomodulatory effects. However, celecoxib itself has only mild suppressive effects on arthritis.
Recently, we reported that a 4-trifluoromethyl analogue of celecoxib (TFM-C) with 205-fold lower COX-2-inhibitory
activity inhibits secretion of IL-12 family cytokines through a COX-2-independent mechanism that involves Ca2
+-mediated intracellular retention of the IL-12 polypeptide chains. In this study, we explored the capacity of TFM-C
as a new therapeutic agent for arthritis.
Methods: To induce collagen-induced arthritis (CIA), DBA1/J mice were immunized with bovine type II collagen
(CII) in Freund’s adjuvant. Collagen antibody-induced arthritis (CAIA) was induced in C57BL/6 mice by injecting
anti-CII antibodies. Mice received 10 μg/g of TFM-C or celecoxib every other day. The effects of TFM-C on clinical
and histopathological severities were assessed. The serum levels of CII-specific antibodies were measured by ELISA.
The effects of TFM-C on mast cell activation, cytokine producing capacity by macophages, and neutrophil
recruitment were also evaluated.
Results: TFM-C inhibited the severity of CIA and CAIA more strongly than celecoxib. TFM-C treatments had little
effect on CII-specific antibody levels in serum. TFM-C suppressed the activation of mast cells in arthritic joints. TFM-
C also suppressed the production of inflammatory cytokines by macrophages and leukocyte influx in thioglycollate-
induced peritonitis.
Conclusion: These results indicate that TFM-C may serve as an effective new disease-modifying drug for treatment
of arthritis, such as rheumatoid arthritis.
Introduction
In the past decade, a series of potent new biologic thera-
peutics have demonstrated remarkable clinical efficacy
in several autoimmune diseases, including rheumatoid
arthritis (RA). In the case of RA, a chronic progressive
autoimmune disease that targets joints and occurs in
approximately 0.5 to 1% of adults, biologic agents, such
as TNF inhibitors, have proven effective in patients not
responding to disease-modifying anti-rheumatic drugs,
such as methotrexate. However, about 30% of patients
treated with a TNF inhibitor are primary non-respon-
ders. Moreover, a substantial proportion of patients
experience a loss of efficacy after a primary response to
a TNF inhibitor (secondary non-responders) [1-3]. More
recently, as new therapies have become available, includ-
ing biological agents targeting IL-6, B cells and T cells,
it has become clear that a notable proportion of patients
respond to these new biological agents even among pri-
mary and secondary non-responders to TNF inhibitors
[3-10]. These individual differences in response to each
agent highlight the difficulty and limit of treating multi-
factorial disease by targeting single cytokine or single
cell type. Patient-tailored therapy might be able to
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overcome this issue, but good biomarkers to predict
treatment responses have not yet been elucidated.
Therefore, as described above, biological drugs have
limited values. In addition, such drugs may be accompa-
nied by serious side effects [11,12]. Furthermore, the
high cost of these biological drugs may make access to
these reagents prohibitive for the general public. Alter-
native therapeutic options, such as small molecule-based
drugs, continue to be an important challenge.
The involvement of prostaglandin pathways in the
pathogenesis of arthritis has been shown in animal mod-
els by using mice lacking genes, such as cycolooxygen-
ase-2 (COX-2), prostaglandin E synthase, or prostacyclin
receptor [13-15]. As COX-2 knockout mice normally
develop autoreactive T cells in collagen-induced arthritis
(CIA) [13], prostaglandin pathways appear to be
involved mainly in the effector phase of arthritis. How-
ever, treatment with celecoxib, a prototype drug belong-
ing to a new generation of highly specific COX-2
inhibitors has been reported to have only mild suppres-
sive effects on animal models of arthritis, and strong
inhibition of arthritis was achieved only when mice were
treated in the combination of celecoxib with leukotriene
inhibitors [16-19]. In humans, although celecoxib is
widely used as an analgesic agent in patients with RA or
osteoarthritis, there is no evidence that celecoxib ther-
apy modulates the clinical course of RA. In addition,
recently it has been shown that celecoxib enhances
TNFa production by RA synovial membrane cultures
and human monocytes [20].
Celecoxib has been reported to exhibit COX-2-inde-
pendent effects, such as tumor growth inhibition and
immunomodulation [21,22]. Previously, we demon-
strated that celecoxib treatment suppressed experimen-
tal autoimmune encephalomyelitis (EAE) in a COX-2
independent manner [22]. We recently developed a tri-
fluoromethyl analogue of celecoxib (TFM-C; full name:
4-[5-(4-trifluoromethylphenyl)-3-(trifluoromet-hyl)-1H-
pyrazol-1-yl]benzenesulfonamide), with 205-fold lower
COX-2-inhibitory activity. In studies using recombinant
cell lines, TFM-C inhibited secretion of the IL-12 family
cytokines, IL-12, p80 and IL-23, through a COX-2-inde-
pendent, Ca2+-dependent mechanism involving chaper-
one-mediated cytokine retention in the endoplasmic
reticulum coupled to degradation via the ER stress pro-
tein HERP [23,24]. In the present study, we demonstrate
that TFM-C inhibits innate immune cells and animal
models of arthritis, including CIA and type II collagen
antibody-induced arthritis (CAIA), in contrast to the
limited inhibitory effect of celecoxib. TFM-C suppresses
the activation of mast cells in arthritic joints. Moreover,
TFM-C treatment suppresses the production of inflam-
matory cytokines by macrophages and leukocyte recruit-
ment. These findings indicate that TFM-C may serve as
an effective new drug for the treatment of arthritis,
including RA.
Materials and methods
Differentiation and stimulation of U937 cells
Human U937 cells were obtained from the American
Type Culture Collection (Rockville, MD, USA) and cul-
tured in RPMI 1640 supplemented with 10% FCS. To
differentiate U937 cells, 5 × 105 cells were treated with
PMA (25 ng/ml) for 24 hours. At 22 hours of PMA
treatment, 50 μM of TFM-C was added for 2 hours.
Subsequently, cells were stimulated with 5 μg/ml of LPS
and PMA (25 ng/ml) for 0, 3, 6, 12 and 24 hours in the
presence or absence of TFM-C. Supernatants were har-
vested and assayed for cytokine production by means of
Quansys Q-Plex™ Array (Quansys Bioscience, Logan,
Utah, USA). RNA isolation was performed following the
manufacturer’s instructions (Macherey-Nagel, Düren,
Germany).
Quantitative RT-PCR (qPCR)
A total of 200 ng of RNA extracted from U937 cells was
retrotranscribed to cDNA using random primers
according to the manufacturer’s protocol (Applied Bio-
systems, Carlsbad, California, USA). qPCR was per-
formed with the Supermix for SsoFast EvaGreen
(Biorad, Hercules, California, USA) on a 7500 Fast Real-
Time PCR System (Applied Biosystems). For each target
gene, qPCR QuantiTect Primer Assays were used (Qia-
gen Hilden, Germany). For each sample, expression
levels of the transcripts of interest were compared to
that of endogenous GAPDH. The levels of mRNA are
calculated as 2-Ct.
Quansys Q-Plex™ Array chemiluminescent
A total of 30 μl of medium from differentiated U937
cells treated with PMA/LPS/TFM-C or LPS/PMA were
analyzed. Human Cytokine Stripwells (16-plex) were
used following the manufacturer’s instructions. The
image was acquired using Bio-Rad Chemidoc camera
and analyzed with Q-View Software (Quansys
Bioscience, Logan, Utah, USA)
DAPI staining
Differentiated U937s were treated with LPS/PMA/TFM-
C for 6, 12 and 24 hours and then fixed with 2% PFA.
The cells were washed three times with PBS and then
incubated with DAPI (1:50000; Molecular Probes, Carls-
bad, California, USA) in PBS. Coverslips were embedded
in Fluoro-Gel (Electron Microscopy Science, Hatfield,
Pennsylvania, USA). Images were recorded using the
ApoTome system (AxioVision, Carl Zeiss, Inc., Oberko-
chen, Germany) and analyzed using the ImageJ program
(version 1.40, Bethesda, Maryland, USA).
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AlarmBlue staining of U937 cells
The number of viable cells was tested at 6, 12, and 24
hours after TFM-C exposure by adding the AlamarBlue
reagent (AbD Serotec, Cambridge, UK). Absorbance was
measured at wavelengths of 570 nm and 600 nm after
required incubation, using a Varioskan Flash (Thermo
Fisher Scientific, Fremont, CA, USA). Absorbance values
of samples were normalized with values of the cell cul-
ture media without cells. The results are presented as
the proportion of viable cells, calculated by dividing the
absorbance values of drug-treated samples by the absor-
bance values of untreated control samples.
Mice
DBA1/J mice were purchased from Oriental Yeast Co.,
Ltd. (Tokyo, Japan). C57BL/6J (B6) mice were pur-
chased from CLEA Laboratory Animal Corp. (Tokyo,
Japan). Animal care and use were in accordance with
institutional guidelines and all animal experiments
were approved by the Institutional Animal Care and
Use Committee of the National Institute of
Neuroscience.
Induction of CIA
DBA1/J male mice (n = 5 to 6 per group, 7 to 8 weeks
old) were immunized intradermally at the base of the
tail with 150 μg of bovine type II collagen (CII) (Col-
lagen Research Center, Tokyo, Japan) emulsified with an
equal volume of complete Freund’s adjuvant (CFA), con-
taining 250 μg of H37Ra Mycobacterium tuberculosis
(Mtb) (Difco, Detroit, MI, USA). DBA1/J mice were
boosted 21 days after immunization by intradermal
injection with 150 μg of CII emulsified with incomplete
Freund’s adjuvant (IFA).
Induction of CAIA
B6 female mice (n = 5 to 6 per group, 7 to 8 weeks old)
were injected intravenously with 2 mg of a mixture of
anti-CII monoclonal antibodies (mAbs) (Arthrogen-CIA
mAb (Chondrex. LLC. Seattle, WA, USA)), and two
days later with 50 μg of lipopolysaccharide (LPS) was
injected intraperitoneally.
Clinical assessment of arthritis
Mice were examined for signs of joint inflammation and
scored as follows: 0: no change, 1: significant swelling
and redness of one digit, 2: mild swelling and erythema
of the limb or swelling of more than two digits, 3:
marked swelling and erythema of the limb, 4: maximal
swelling and redness of the limb and later, ankylosis.
The average macroscopic score was expressed as a
cumulative value for all paws, with a maximum possible
score of 16.
Thioglycollate-induced peritonitis
Mice were injected with 1 ml of 4% sterile thioglycollate
intraperitoneally. Four hours later, mice were killed and
peritoneal lavage fluid was collected by washing the
peritoneal cavity with cold PBS containing 5 mM EDTA
and 10 U/ml heparin.
Administration of TFM-C or celecoxib
TFM-C and celecoxib were synthesized as previously
described [23]. We injected TFM-C or celecoxib intraperi-
tonealy (i.p.) in 0.5% Tween/5% DMSO/PBS. In CIA
experiments, mice received 10 μg/g TFM-C or celecoxib
every other day from 21 days after immunuization. In
CAIA, we injected the mice with 10 μg/g of TFM-C or cel-
ecoxib every other day starting at two days before disease
induction. In thioglycollate-induced peritonitis experi-
ments, mice received 10 μg/g of TFM-C or celecoxib two
days and one hour before thioglycollate injection. The
control animals were injected with vehicle alone.
Histopathology
Arthritic mice were sacrificed and all four paws were
fixed in buffered formalin, decalcified, embedded in par-
affin, sectioned, and then stained with H&E. Histological
assessment of joint inflammation was scored as follows:
0: normal joint, 1: mild arthritis: minimal synovitis with-
out cartilage/bone erosions, 2: moderate arthritis: syno-
vitis and erosions but joint architecture maintained, 3:
severe arthritis; synovitis, erosions, and loss of joint
integrity. The average of the macroscopic score was
expressed as a cumulative value of all paws, with a max-
imum possible score of 12.
Mast cells in synovium were visually assessed for
intact versus degranulating mast cells using morphologic
criteria. Mast cells were identified as those cells that
contained toluidine blue-positive granules. Only cells in
which a nucleus was present were counted. Degranulat-
ing cells were defined by the presence of granules out-
side the cell border with coincident vacant granule
space within the cell border as described previously [25].
Measurement of CII specific IgG1 and IgG2a
Bovine CII (1 mg/ml) was coated onto ELISA plates
(Sumitomo Bakelite, Co., Ltd, Tokyo, Japan) at 4°C over-
night. After blocking with 1% bovine serum albumin in
PBS, serially diluted serum samples were added onto
CII-coated wells. For detection of anti-CII Abs, the
plates were incubated with biotin-labeled anti-IgG1 and
anti-IgG2a (Southern Biotechnology Associates, Inc.,
Brimingham, AL, USA) or anti-IgG Ab (CN/Cappel,
Aurora, OH, USA) for one hour and then incubated
with streptavidin-peroxidase. After adding a substrate,
the reaction was evaluated as OD450 values.
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Stimulation of or macrophages
B6 mice received 10 μg/g of TFM-C or control vehicle
on Day 0 and Day 2, and on Day 3, splenic macrophages
were collected and were stimulated by LPS in vitro in
the presence of TFM-C or vehicle.
Detection of cytokines
Cytokine levels in the culture supernatant were deter-
mined by using a sandwich ELISA. The Abs for IL-1b
ELISA were purchased from BD Biosciences (San Jose,
CA, USA) and the ELISA Abs for IL-6 and TNFa were
purchased from eBioscience (San Diego, CA, USA).
Statistical analysis
CIA and CAIA clinical or pathological scores for groups
of mice are presented as the mean group clinical score
+ SEM, and statistical differences were analyzed with a
non-parametric Mann-Whitney U-test. Data for cyto-
kines were analyzed by an unpaired t-test.
Results
TFM-C inhibits cytokine secretion from activated U937
cells concomitant with induction of an ER stress response
In a recombinant cell system, TFM-C inhibits IL-12
secretion via a mechanism involving the induction of ER
stress coupled to intracellular degradation of the cyto-
kine polypeptide chains via the ER stress protein HERP
[23,24,26]. In order to verify whether the cytokine secre-
tion-inhibitory effect of TFM-C extends to natural cyto-
kine producer cells, we assessed its effect using PMA/
LPS-activated U937 macrophages, a well-known source
of multiple cytokines. TFM-C potently blocked secretion
of IL-b, IL-6, IL-8, IL-10, IL-12 and TNF-a (Figure 1A,
C). By means of QPCR, TFM-C was found to suppress
mRNA production of IL-10 over the course of the
experiment, and at 12 and 24 h of TFM-C treatment, of
IL-1b. Virtually no effect was seen on mRNA produc-
tion of TNF-a and IL-8, while TFM-C increased IL-6
mRNA between 6 and 12 h. To verify whether TFM-C
induced an ER stress response in U937 cells, we mea-
sured mRNA of HERP and IL-23p19, both of which
have been associated with induction of ER stress
[24,26,27]. This showed significant up-regulation of both
genes by TFM-C while the housekeeping gene GAPDH
was not affected (Figure 1D). Viability of U937 cells fol-
lowing exposure to TFM-C was assessed using two dif-
ferent methods (Figure 1B), and showed a limited
percentage of apoptotic cells not exceeding 15 to 20%
following 12 to 24 h of treatment. Thus, TFM-C blocks
cytokine secretion in natural producer cells by ER
stress-related mechanisms that may involve repressive
effects on both cytokine mRNA production as well as
on post-transcriptional and -translational events
involved in cytokine secretion, such as the ER-retention
coupled to HERP-mediated degradation identified before
for IL-12 [23,24,26]. However, of the TFM-C-sensitive
cytokines identified in this experiment, IL-1b follows an
unconventional protein secretion route involving
Figure 1 Effect of TFM-C on cytokine production from
activated U937 macrophages. A. Lay-out of cytokine-specific
antibody spots in the 16-plex cytokine Stripwell array (upper image)
and visualization of cytokine-specific chemiluminescence in culture
medium of LPS/PMA-treated U937 cells in the absence or presence
of TFM-C (lower images). The grey-shaded cytokines in the upper
images are those showing the highest production in LPS/PMA-
treated U937 cells at 24 h. B. Effect of TFM-C treatment (50 μM) on
the viability of macrophages (PMA-stimulated U937 cells). Apoptotic
cells were measured by DAPI staining, and the percentage of
damaged DNA and condensed chromatin was calculated following
6, 12 and 24 h of TFM-C treatment (upper graph). Metabolic activity
of cells, measured by AlarmBlue®, was expressed as growth
inhibition percentage of untreated controls for 6, 12 and 24 h of
TFM-C treatment (lower graph). Bars show average of three
independent experiments with corresponding error bars. C.
Quantification of the kinetics of cytokine secretion and mRNA
production (IL-1b, IL-6, IL-8, IL-10 IL-12 and TNF-a) in differentiated
macrophages treated with LPS/PMA in the absence (open squares)
or presence (solid circles) of TFM-C. All values represent the
averages of three independent experiments. For each cytokine, the
upper graph represents amount of secreted cytokine quantified
using Quansys 16-plex Stripwells, while the lower graph represents
cytokine-specific mRNA quantified by QPCR. Asterisks indicate
significant differences at * P < 0.05 between TFM-C-treated and
-untreated cells at each time point using Student’s t-test. D. Effect
of 50 μM TFM-C on IL-23p19, HERP and GAPDH mRNAs (QPCR) in
differentiated macrophages, stimulated by LPS and PMA. The levels
of mRNA levels are shown as 2-Ct. Asterisks indicate significant
differences at * P < 0.05 compared with baseline condition LPS/
PMA-only using Student’s t-test.
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exocytosis of endolysosome-related vesicles not derived
from the ER/Golgi system [28]. Given its blockage by
TFM-C, which can not be explained by partial suppres-
sion of mRNA levels only, this indicates that TFM-C
may suppress secretion of cytokines via interfering with
both conventional ER-dependent and unconventional
ER-independent transit routes.
TFM-C inhibits CIA
First, we examined the effect of TFM-C on CIA induced
by immunizing DBA1/J mice with type II collagen. As
shown in Figure 2A, administration of TFM-C strongly
suppressed the severity of arthritis compared with vehi-
cle-treated mice (P-value, < 0.05 by Mann-Whitney U-
test compared with control from Day 26 and Day 36.).
In contrast, administration of celecoxib showed only a
mild suppressive effect on CIA, which is consistent with
a previous report [19] (P-value, < 0.05 by Mann-Whit-
ney U-test compared with control at Day 29 and Day
31.) In addition to visual scoring, we analyzed the histo-
logical features in the joints of four paws from TFM-C-,
celecoxib- or vehicle-treated mice 37 days after disease
induction. Quantification of the histological severity of
arthritis is shown in Figure 2B and typical histological
features are demonstrated in Figure 2C. Arthritis was
not apparent in joints treated with TFM-C (Figure 2C,
rightmost panel) compared to the severe arthritis with
massive cell infiltration, cartilage erosion and bone
destruction seen in joints of animals treated with vehicle
(Figure 2C, leftmost panel). Both the clinical scores and
pathological features of arthritis were significantly less
severe in TFM-C-treated mice (Figure 2A-C). The
pathological features, including cell infiltration and
destruction of cartilage and bone, were slightly less
severe in celecoxib-treated mice even though there is no
statistically significant difference compared to vehicle-
treated mice (Figure 2B). We next examined anti-CII
antibody in TFM-C-, celecoxib- or vehicle-treated
arthritic mice. There was a trend for reduction in both
IgG1 and IgG2a isotypes as well as total IgG anti-CII in
TFM-C-treated mice compared to vehicle-treated mice
(Figure 2D), but the difference did not reach statistical
significance. These results indicate that TFM-C pos-
sesses a potent inhibitory effect on CIA compared to
vehicle or celecoxib. However, TFM-C treatment had
little effect on CII-specific responses.
TFM-C inhibits CAIA
Although TFM-C treatment suppressed clinical and
pathological severities of CIA, CII-specific antibody
levels were not reduced by TFM-C treatment. There-
fore, we hypothesized that TFM-C treatment may have
a strong inhibitory effect on the effector phase of arthri-
tis. To test this hypothesis, we examined the effect of
TFM-C on CAIA induced by injecting a mixture of
monoclonal antibodies against type II collagen (CII) fol-
lowed by lipopolysaccharide (LPS) administration two
days later. The major players in CAIA are innate
immune cells while adaptive immune cells are not
required for disease development. Therefore, CAIA has
value as an animal model to study the effector phase of
arthritis. In vehicle-treated mice, severe arthritis
occurred one week after CII antibody injection, and
administration of celecoxib inhibited arthritis slightly
(Figure 3A). In contrast, administration of TFM-C sig-
nificantly suppressed CAIA compared to vehicle or cele-
coxib treatment. We next analyzed the histological
features in the joints of four paws from vehicle-, TFM-
C- and celecoxib-treated mice 12 days after disease
induction. Quantification of the histological severity of
arthritis is shown in Figure 3B and typical histological
features are presented in Figure 3C. Massive cell infiltra-
tion, cartilage erosion, and bone destruction were
observed in joints of vehicle-treated or celecoxib-treated
mice but not in those of TFM-C-treated mice (Figure
Figure 2 The effect of TFM-C on CIA. A. Clinical scores of CIA in
DBA1/J mice treated with 10 μg/g TFM-C (closed circles), celecoxib
(open triangles) or vehicle (open squares) every other day from 21
days after immunization. The data shown are pooled from two
similar experiments. Error bars represent + SEM of 10 to 12 mice per
group. * P < 0.05 compared with control group. * P < 0.05
compared with both control and celecoxib-treated groups. B.
Quantification of histological assessment of joints 37 days after
induction of CIA. Result shown is the mean + SEM of five mice per
group. * P < 0.05, TFM-C-treated versus vehicle-treated group. * P <
0.05, celecoxib-treated versus TFM-C-treated group. C.
Representative histological feature of joints in vehicle-treated (left),
TFM-C-treated (right) and celecoxib-treated (middle) mice. (H&E
stained; original magnification × 40). D. The effect of TFM-C on CII-
specific response. CII-specific antibody responses in vehicle- (open
bars), TFM-C- (filled bars) and celecoxib-treated (gray bars) group.
Individual serum samples were obtained at Day 37 after the
induction of arthritis and were analyzed as indicated in Materials
and Methods. Data represent the mean + SEM of five mice per
group.
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3B, C). These results indicate that TFM-C exhibits a
strong disease inhibitory effect in CAIA in contrast to
vehicle or celecoxib.
TFM-C inhibits the mast cell activation in CAIA
Next, we sought to understand the mechanism through
which TFM-C treatment suppressed arthritis in CAIA.
Since mast cells have been demonstrated to be critical
for initiation of antibody-induced arthritis [29], we eval-
uated the effect of TFM-C on the activation of mast
cells. Because degranulation is the clearest histological
hallmark of mast cell activation, joint mast cells were
visually assessed for an intact versus degranulating phe-
notype after staining with toluidine blue. The proportion
of degranulated mast cells was significantly lower in
TFM-C-treated mice compared to that in celecoxib- or
vehicle-treated mice (Figure 4A, B).
TFM-C supresses the activation of macrophages
Innate immune cells and inflammatory cytokines, such
as IL-1 and TNF-a are critical for disease development
in CAIA [30]. Thus, we next determined the effect of
TFM-C on the production of inflammatory cytokines
from macrophages. Splenic macrophages from mice
treated with TFM-C, celecoxib or control vehicle, were
stimulated with LPS ex vivo, and the cytokines in the
culture supernatants were measured by ELISA. The
production of IL-1, IL-6 and TNF-a from macrophages
was efficiently suppressed in TFM-C-treated mice com-
pared to vehicle-treated mice (Figure 5). In celecoxib-
treated mice, although the production of IL-1b was
decreased, the production of other cytokines such as IL-
6 and TNF-a was not suppressed, and the IL-6 produc-
tion was even enhanced compared to vehicle-treated
mice.
TFM-C suppresses leukocyte influx in thioglycollate-
induced peritonitis
The other key players in antibody-induced arthritis are
neutrophils [31-34]. Neutrophils are recruited to joint
tissue and depletion of neutrophils has been shown to
supress disease susceptibility and severity in CAIA [35].
An intraperitoneal injection of thioglycollate causes leu-
kocytes influx into the peritoneum from bone marrow
and circulation, and neutrophils are the major cell
population which first emigrate to the peritoneal cavity.
To assess the effect of TFM-C on neutrophil recruit-
ment, mice were treated with TFM-C, celecoxib or con-
trol vehicle, and thioglycollate was injected
intraperitoneally. Leukocyte cell numbers in the perito-
neal cavity four hours after thioglycollate injection were
comparable between control and celecoxib-treated
groups (Figure 6). However, the peritoneal infiltrating
cell numbers were reduced in mice treated with TFM-C,
suggesting the suppressive effect of TFM-C on neutro-
phil recruitment.
Taken together, these results indicate that the activa-
tion of innate immune cells, including mast cells,
macrophages, and neutrophils, is suppressed in TFM-C-
treated mice but not in celecoxib-treated mice.
Discussion
In the present study we demonstrate, using arthritis
models, that TFM-C, a celecoxib analogue with 205-fold
lower COX-2-inhibitory activity, inhibits autoimmune
disease. TFM-C differs from celecoxib by the substitu-
tion of the 4-methyl group by a trifluoromethyl group.
This substitution drastically increases the IC50s for inhi-
bition of COX1 (15 μM to >100 μM for celecoxib and
TFM-C, respectively) and COX2 (0.04 μM to 8.2 μM,
respectively), but does not affect the apoptotic index
measured in PC3 prostate cancer cells, indicating inde-
pendence between structural requirements for COX-2
inhibition and apoptosis induction [36]. Celecoxib per-
turbs intracellular calcium by blocking ER Ca2+
ATPases, and this activity is shared with TFM-C [23,37].
In a HEK293 recombinant cell system, this Ca2+ pertur-
bation is associated with inhibition of secretion and
altered intracellular interaction of IL-12 polypeptide
chains with the ER chaperones calreticulin and ERp44,
and results in the interception of IL-12 by HERP
Figure 3 The effect of TFM-C on CAIA. A. Clinical scores of CAIA
in B6 mice treated with 10 μg/g TFM-C (closed circles), celecoxib
(open triangles) or vehicle (open squares) every other day from two
days before CAIA induction. * P < 0.05 compared with control
group, * P < 0.05 compared with both control and celecoxib-
treated groups. Results shown are the mean + SEM of five mice per
group. The data shown are from a single experiment representative
of two similar experiments. B. Quantification of histological
assessment of joints 12 days after induction of AIA shown in A.
Results shown are the mean + SEM of five mice per group. * P <
0.05 control versus TFM-C group, * P < 0.05 celecoxib versus TFM-C
-treated group. C. Representative histological feature of joints in
vehicle-treated (left), TFM-C-treated (middle) and celecoxib-treated
(right) mice. (H&E stained; original magnification × 40).
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followed by degradation of the cytokine [23,24,26].
While IC50s for inhibition of IL-12 secretion by cele-
coxib or TFM-C are similar [23,24], in the present
paper, we show that TFM-C inhibits production of var-
ious cytokines from activated macrophages (Figures 1
and 5) and exerts a strikingly stronger inhibitory effect
on arthritis models compared to celecoxib. Given that
the main biological difference between celecoxib and
TFM-C resides in the extent of COX-1 and -2 inhibi-
tion, it is, therefore, likely that the less potent effect of
TFM-C on COX1/2 inactivation is a contributing, dis-
ease-limiting rather than disease-promoting factor in
these arthritis models. Indications supporting this con-
cept come from a study showing increased LPS-induced
macrophage production of TNF-a by inactivation of
COX-2 with celecoxib [38]. Up-regulation of TNF-a by
celecoxib was also reported in human PBMCs, rheuma-
toid synovial cultures and whole blood [20]. The relation
between the anticipated extent of COX inhibition and
production of TNF-a was observed in the present study
(Figure 5), where activated macrophages showed a ten-
dency toward increased or decreased TNF-a production
in the presence of celecoxib or TFM-C, respectively,
compared to vehicle-treated cells. In this cell system
(Figure 5), celecoxib significantly increased production
of the pro-inflammatory cytokine IL-6 while TFM-C
suppressed it. Pending future mechanistic studies, this
data indicate that prostaglandin-mediated suppressive
effects, or other, as yet to be identified differential TFM-
C/celecoxib-related effects on TNF-a production may
extend to other cytokines as well, and provide an impor-
tant clue as to the more potent beneficial effects of
TFM-C compared to celecoxib in the arthritis models
presented here.
The suppression of antibody-induced arthritis, which
requires innate but not acquired immune cells
[29-34,39], suggests that TFM-C also inhibits the activa-
tion of innate immune cells while celecoxib does not. In
fact, TFM-C suppresses the production of inflammatory
cytokines from macrophages and the activation of mast
cells as well as the subsequent recruitment of leuko-
cytes. Mast cells are essential for the initiation of anti-
body-induced arthritis [29]. Moreover, mast cells are
present in human synovia [40-43] and are an important
Figure 4 TFM-C inhibits the mast cell activation in CAIA. CAIA was induced in B6 mice and the mice were then treated with 10 μg/g TFM-C,
celecoxib or vehicle as described in Figure 2. A. Quantification of degranulated mast cells in synovium of joints 12 days after induction of CAIA. *
P < 0.05, compared with vehicle-treated group. * P < 0.05, compared with celecoxib-treated group. Results shown are the mean + SEM of six
mice per group and were pooled from two experiments. B. Hisopathologic features of degranulated or intact mast cells in joints of
representative vehicle-, celecoxib- and TFM-C- treated mice (toluidine blue stained; original magnification, × 100). White arrows indicate intact
mast cells and black arrows indicate degranulated mast cells.
Figure 5 TFM-C supresses the activation of macrophages. B6 mice recieved 10 μg/g TFM-C, celecoxib or vehicle on Day 0 and Day 2, and
on Day 3, splenic macrophages were collected and were stimulated by LPS in vitro in the presence of TFM-C, celecoxib or vehicle. Cytokines
were detected by ELISA. IL-1b and IL-6 were measured 24 h after stimulation. TNF-a was measured six hours after stimulation. The data shown
are from a single experiment representative of three similar experiments. * P < 0.05 compared with control group, * P < 0.05 compared with
celecoxib-treated group.
Chiba et al. Arthritis Research & Therapy 2012, 14:R9
http://arthritis-research.com/content/14/1/R9
Page 7 of 10
source of both proteases and inflammatory cytokines,
including IL-17, in patients with rheumatoid arthritis
[42-44]. The clear difference between the effects of
TFM-C and celecoxib on the suppression of mast cell
activation could explain the differential impact of these
compounds on arthritis models. Mast cells are impor-
tant not only in arthritis but also in other conditions,
such as allergy, obesity and diabetes [45]. Therefore, the
suppression of mast cell activation by TFM-C may be
applicable for the inhibition of these diseases in addition
to autoimmune diseases.
Cytokines and chemokines, such as TNF-a and MCP-
1, produced by macrophages, are suggested to play
important roles for neutrophil influx in thioglycollate-
induced peritonitis [46]. Mast cells were shown to pro-
duce TNF-a, which recruits neutrophils into the perito-
neum in an immune complex peritonitis model [47].
Thus, it is likely that TFM-C suppressed macrophages
and mast cells produce such chemoattractants, which in
turn inhibited neutrophil influx into the peritoneum.
However, it is also possible that TFM-C directly sup-
pressed neutrophil activation. Further studies are
required to address this possibility.
As described above, the major players in CAIA are
innate immune cells, while adaptive immune cells are not
required for disease development. Therefore, CAIA has
value as an animal model for the study of the effector
phase of arthritis. However, it is well known that adaptive
immune cells play a significant role in the pathogenesis
of RA and the strongest genetic link in RA is the associa-
tion with HLA-DR, which is thought to present autoanti-
gens to T cells. The activation of T cells and B cells is
believed to initiate and/or enhance the effector inflam-
mation phase of arthritis. In fact, massive infiltration of T
and B cells is observed in RA synovium. Therefore, the
ideal therapeutic agents for RA are those displaying the
capacity to suppress both the induction and effector
phases of arthritis. TFM-C treatment suppresses CIA,
which requires both innate and adaptive immune cells
for the development of arthritis. We previously demon-
strated that celecoxib treatment suppresses EAE induced
by immunizing B6 mice with myelin oligodendrocyte gly-
coprotein35-55 (MOG) peptide [22]. The suppression of
EAE by celecoxib was COX-2 independent and was
accompanied by reduced IFN-g production by MOG-
reactive T cells. We observed a trend of reduced anti-CII
antibody levels in serum upon TFM-C treatment. As
TFM-C inhibited secretion of both recombinant IL-12
and IL-23 using a pIND ponasterone-inducible vector
system in HEK293 cells [23,24], TFM-C treatment may
have also influenced CII-specific immune responses by
suppressing antigen-presenting cells.
Specific inhibition of COX-2 has some adverse effects.
Rofecoxib, a highly specific COX-2 inhibitor, was with-
drawn from the world market because of an increased
rate of cardiovascular events in patients with colorectal
polyps [48]. Celecoxib was also shown to augment cardi-
ovascular and thrombotic risk in colorectal adenoma
patients, especially in the subgroup suffering from pre-
existing atherosclerotic heart disease [49]. Moreover,
inhibition of COX-2 activity has been reported to
exacerbate brain inflammation by increasing glial cell
activation [50]. It has been suggested that the inhibition
of COX-2-dependent prostaglandin I2 from endothelial
cells may be the major cause of thrombosis [51]. As the
COX-2-inhibitory activity of TFM-C is 205-fold lower
than that of celecoxib, the arthritis suppression by
TFM-C appears to be independent of COX-2 inhibition.
Therefore, TFM-C, which has strong immunoregulatory
abilities but low COX-2-inhibitory activity, could serve
as a new disease-modifying agent to prevent the pro-
gression of autoimmune diseases such as RA.
Conclusions
In summary, TFM-C, a trifluoromethyl analogue of cele-
coxib, inhibits arthritis despite the fact that TFM-C pos-
sesses very low COX-2-inhibitory activity. The most
striking features of TFM-C are its inhibitory effect on
the activation of innate immune cells and its suppres-
sion of arthritis compared to celecoxib. TFM-C treat-
ment suppressed both CIA and CAIA by targeting
innate immune cells, which are involved in both the
induction and the effector phases of arthritis inflamma-
tion. Taking these data together, TFM-C may serve as
an effective therapeutic drug for arthritis, including RA.
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